CEN Biotech, Inc.
CENBF · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | 0.04 | -0.03 |
| FCF Yield | 289.56% | -10.04% | 4.04% | 1.94% |
| EV / EBITDA | 11.45 | -36.19 | -18.20 | -28.38 |
| Quality | ||||
| ROIC | -30.51% | -8.58% | -13.66% | -10.90% |
| Gross Margin | 100.00% | 90.52% | 84.82% | 45.21% |
| Cash Conversion Ratio | 1.16 | 0.18 | -0.26 | -0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.57% | 883,750.64% | 1,026,257.51% | 1,098,899.64% |
| Free Cash Flow Growth | 454.04% | -312.72% | 2.24% | 157.17% |
| Safety | ||||
| Net Debt / EBITDA | 11.12 | -29.74 | -14.46 | -18.70 |
| Interest Coverage | -19.46 | -5.17 | -10.24 | -7.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 158.30 | -4,978.97 | -2,414.32 | -168.77 |